

# Contents

<b>1</b>	<b>An Overview of Inflammatory Arthritis</b> .....	1
	Introduction .....	2
	What Are the Inflammatory Arthropathies? .....	2
	Historical Perspectives .....	3
	Diagnosis.....	4
	The Concept of Classification Criteria .....	4
	Rheumatoid Arthritis.....	5
	Ankylosing Spondylitis .....	5
	Psoriatic Arthritis .....	9
	Other Spondyloarthropathies .....	10
	References .....	11
<b>2</b>	<b>Epidemiology and Pathology</b> .....	13
	Epidemiology of Rheumatoid Arthritis .....	14
	Epidemiology of Seronegative Arthritis .....	14
	Aetiology of Inflammatory Arthritis .....	16
	Rheumatoid Arthritis.....	16
	Seronegative Spondyloarthropathies.....	17
	Pathology of Inflammatory Arthritis.....	17
	Histology .....	17
	Lymphocytes .....	18
	Cytokines.....	19
	Chemokines.....	20
	Metalloproteinases .....	20
	Adhesion Molecules, Angiogenesis and Other Mediators .....	20
	References .....	20

<b>3 Clinical Features</b> . . . . .	23
Synovitis of Peripheral Joints . . . . .	24
Symptoms . . . . .	24
Joint Swelling and Tenderness . . . . .	24
Peripheral Joints Involved . . . . .	25
Rheumatoid Arthritis . . . . .	25
Psoriatic Arthritis . . . . .	28
Other Forms of Spondyloarthropathies . . . . .	29
Enthesitis . . . . .	29
Spinal Disease . . . . .	30
Ankylosing Spondylitis . . . . .	30
Other Types of Spondyloarthritis . . . . .	31
Rheumatoid Arthritis . . . . .	31
Systemic Features . . . . .	31
Clinical Course . . . . .	32
Onset of Rheumatoid Arthritis . . . . .	32
Established Rheumatoid Arthritis . . . . .	33
Other Inflammatory Arthropathies . . . . .	33
Undifferentiated Early Arthritis . . . . .	33
Extra-articular Disease . . . . .	34
Rheumatoid Arthritis . . . . .	34
Other Inflammatory Arthropathies . . . . .	36
References . . . . .	37
<b>4 Clinical and Laboratory Assessments</b> . . . . .	39
Role of Assessments . . . . .	40
Clinical Assessments . . . . .	40
Joint Counts . . . . .	40
Global Assessments . . . . .	43
Pain Scores . . . . .	45
Functional Assessments . . . . .	46
Generic Health Status Measures . . . . .	47
SF-36 . . . . .	48
EuroQol . . . . .	48
Laboratory Assessments . . . . .	49
Acute Phase Response . . . . .	49
Multi-biomarker Disease Activity (MBDA) Tests . . . . .	51

Rheumatoid Factor.....	51
Antibodies to Citrullinated Protein Antigens. . . .	52
Imaging.....	53
X-Rays in Rheumatoid Arthritis.....	53
Ultrasound in Rheumatoid Arthritis.....	55
Magnetic Resonance Imaging in Rheumatoid Arthritis.....	56
Imaging in Psoriatic Arthritis.....	56
Imaging in Ankylosing Spondylitis and Reactive Arthritis.....	57
Combined Measures.....	57
Core Data Set in Rheumatoid Arthritis.....	57
Composite Disease Activity Indices: Disease Activity Score.....	58
Simplified Indices.....	59
American College of Rheumatology (ACR) Response Criteria.....	60
Other Forms of Arthritis.....	60
Outcomes.....	61
Rheumatoid Arthritis.....	61
Psoriatic Arthritis.....	63
Ankylosing Spondylitis.....	63
References.....	63
<b>5 Symptomatic Drug Treatment.....</b>	<b>67</b>
Introduction.....	67
Simple Analgesics.....	68
Paracetamol.....	69
Opioids.....	70
Tramadol.....	71
Buprenorphine.....	72
Codeine and Dihydrocodeine.....	72
Compound Analgesics.....	72
Non-steroidal Anti-inflammatory Drugs (NSAIDs).....	73
Mechanism of Action and Cox I/Cox II Effects..	73
Classification of NSAIDs.....	74

Conventional NSAIDs.....	75
Cox-2 Drugs (COXIBs).....	75
Adverse Reactions to NSAIDs .....	78
Gastrointestinal Adverse Effects .....	79
Cardiovascular Adverse Effects .....	81
Use in Specific Forms of Arthritis .....	82
Rheumatoid Arthritis.....	82
Psoriatic Arthritis and Seronegative	
Spondyloarthritis.....	83
Ankylosing Spondylitis .....	83
References .....	84
<b>6 Disease-Modifying Anti-Rheumatic Drugs .....</b>	<b>87</b>
Background.....	87
Currently Used Conventional DMARDs.....	88
Starting DMARDs.....	89
Monitoring DMARDs.....	89
Stopping DMARDs.....	90
Early and Late Disease .....	91
Intensive Treatment.....	92
Treat to Target .....	92
Seronegative Arthritis.....	93
Changes in Clinical Trials .....	93
Reduction in Joint Counts and Acute	
Phase Proteins.....	93
American College of Rheumatology	
Responses (ACR).....	94
Improved Disability .....	94
Radiological Damage.....	95
Methotrexate .....	96
Background .....	96
Clinical Use and Efficacy.....	97
Adverse Reactions .....	99
Leflunomide .....	100
Background .....	100
Clinical Use and Efficacy.....	101
Adverse Events.....	101
Sulfasalazine .....	102

Other DMARDs .....	103
Injectable Gold .....	103
Hydroxychloroquine .....	104
Ciclosporin .....	105
Azathioprine .....	105
Minor DMARDs .....	105
Combining DMARDs .....	106
Rationale .....	106
Effective Combinations .....	106
Ineffective Combinations .....	107
Intensive Treatments in Early Disease .....	107
Overall Effectiveness of Combinations .....	108
Seronegative Spondyloarthritis .....	108
References .....	109
<b>7 Biologics – An Overview</b> .....	111
Introduction .....	112
Biologic Treatment Pathways .....	114
Rheumatoid Arthritis .....	114
Early Rheumatoid Arthritis .....	115
Psoriatic Arthritis .....	116
Ankylosing Spondylitis .....	116
Health Economic Case for Using Biologics .....	117
References .....	118
<b>8 Anti-Tumour Necrosis Factor-Alpha (TNF-<math>\alpha</math>) Treatment</b> .....	119
Background .....	120
Etanercept .....	122
Infliximab .....	122
Adalimumab .....	123
Certolizumab .....	123
Golimumab .....	123
Indications .....	124
Rheumatoid Arthritis .....	124
Psoriatic Arthritis .....	124
Ankylosing Spondylitis .....	124

Clinical Effects . . . . .	125
Rheumatoid Arthritis . . . . .	125
Psoriatic Arthritis . . . . .	127
Ankylosing Spondylitis . . . . .	127
Safety and Adverse Effects . . . . .	127
Biologics Registries . . . . .	127
Local Injection Site Reactions . . . . .	128
Hypersensitivity Responses . . . . .	128
Infections . . . . .	128
Demyelinating-like Disorders . . . . .	130
Haematological Disorders . . . . .	130
Heart Failure . . . . .	130
Malignancy . . . . .	131
Auto-immune Disorders . . . . .	131
Interstitial Lung Disease . . . . .	131
Psoriasis . . . . .	132
Immune Responses to TNF- $\alpha$ Inhibitors . . . . .	132
Switching Anti-TNF Agents in Cases of Primary or Secondary Failure . . . . .	132
References . . . . .	133
<b>9 B-Cell Inhibition and Other Biologics . . . . .</b>	<b>137</b>
Introduction . . . . .	137
Rituximab . . . . .	138
Background . . . . .	138
B Cells in RA . . . . .	138
Mechanism of Action . . . . .	139
Clinical Indications . . . . .	139
Clinical Efficacy . . . . .	139
Initial and Repeat Courses . . . . .	141
Adverse Reactions . . . . .	141
Infection . . . . .	142
Anti-biologic Antibodies . . . . .	143
Tocilizumab . . . . .	143
Background . . . . .	143
Clinical Use . . . . .	143
Dosing . . . . .	144
Clinical Efficacy . . . . .	144
Adverse Events . . . . .	144
Anti-biologic Antibodies . . . . .	146

Abatacept .....	147
Background .....	147
Clinical Use .....	147
Dosing .....	147
Clinical Efficacy .....	148
Adverse Reactions .....	149
Ustekinumab .....	149
Background .....	149
Clinical Use .....	149
Adverse Events .....	150
Anakinra .....	150
Background .....	150
Clinical Use .....	150
Side-Effects .....	151
References .....	151
<b>10 Steroids</b> .....	155
Background .....	155
Pharmacological Effects .....	156
Effects on Joint Inflammation .....	157
Erosive Progression .....	157
Early Rheumatoid Arthritis .....	158
Treating Flares with Systemic Steroids .....	159
Psoriatic Arthritis and Ankylosing Spondylitis .....	159
Side-Effects .....	159
Local Steroids .....	160
References .....	161
<b>11 Non-drug Treatments</b> .....	163
Background .....	163
Multidisciplinary Teams .....	164
Education and Support .....	165
Promoting Coping .....	165
Promoting Mobility, Function and Participation .....	165
Physiotherapy .....	166
Occupational Therapy .....	168
Podiatry .....	170
Orthopaedic Surgery .....	170
References .....	171

<b>12</b>	<b>Stopping Treatments</b> . . . . .	173
	Introduction . . . . .	173
	Conventional Disease Modifying Drugs (DMARDs) . . . . .	174
	Can Patients Stay on DMARDs? . . . . .	174
	Withdrawing DMARDs in Responders . . . . .	174
	Step-Down DMARD Therapy . . . . .	175
	Observational Studies of DMARD Withdrawal . . . . .	175
	Predicting Flares After DMARD Withdrawal . . . . .	176
	Recommendations in Guidelines . . . . .	176
	Biological Treatments . . . . .	176
	Stopping and Tapering . . . . .	176
	Studies in Rheumatoid Arthritis . . . . .	177
	Studies in Psoriatic Arthritis . . . . .	178
	Studies in Ankylosing Spondylitis . . . . .	178
	Steroids . . . . .	178
	Conclusions . . . . .	179
	References . . . . .	180
<b>13</b>	<b>Emerging Therapies in Rheumatoid Arthritis</b> . . . . .	183
	Introduction . . . . .	184
	Biosimilars . . . . .	184
	Interchangeability of Biosimilars with Existing Agents . . . . .	185
	Drugs in Development . . . . .	186
	JAK Inhibitors . . . . .	186
	Other Kinase Inhibitors . . . . .	188
	PDE4 Inhibitors . . . . .	188
	Future Targets . . . . .	189
	References . . . . .	189
<b>14</b>	<b>Stratified Medicine in Inflammatory Arthritis</b> . . . . .	191
	What Is Stratified Medicine? . . . . .	191
	Why Stratified Medicine Is Needed in Inflammatory Arthritis Patients . . . . .	192
	Existing Research in Stratified Medicine in Inflammatory Arthritis Patients . . . . .	193



Predictors of Disease Course in RA .....	193
Serology .....	193
Smoking .....	193
Alcohol .....	194
Social Deprivation .....	194
Gender .....	194
Genetics .....	195
Predicting RA Severity .....	195
Predictors of Treatment Responses in RA .....	196
Gender .....	196
Smoking .....	196
Serology .....	197
Disease Duration .....	198
Genetics .....	199
Prediction Models for Treatment Responses in RA .....	199
Stratified Medicine in Non-RA Inflammatory Arthropathies .....	200
Psoriatic Arthritis .....	200
Ankylosing Spondylitis .....	201
Current Use of Stratified Medicine in Inflammatory Arthritis Patients .....	201
Conclusion .....	203
References .....	203
<b>Index .....</b>	<b>207</b>